Our analysis revealed several FH-associated mutations in the CHR domain that greatly diminished (R469W and F515L) or abolished (R496W) the ability of PCSK9 to bind LDL in vitro. The gene discussed is PCSK9; the disease is familial hyperaldosteronism.